Provided by Tiger Trade Technology Pte. Ltd.

Moleculin Biotech

0.5930
+0.00240.41%
Post-market: 0.5882-0.0048-0.81%19:35 EDT
Volume:294.18K
Turnover:173.86K
Market Cap:11.55M
PE:-0.06
High:0.6300
Open:0.5874
Low:0.5600
Close:0.5906
52wk High:15.75
52wk Low:0.1614
Shares:19.48M
Float Shares:17.03M
Volume Ratio:0.31
T/O Rate:1.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.7621
EPS(LYR):-28.4188
ROE:-1371.64%
ROA:-84.57%
PB:1.00
PE(LYR):-0.02

Loading ...

Moleculin Says Miracle Trial Posts 37% Interim CRc Rate in Venetoclax-failed AML Patients

Reuters
·
Jul 31

U.S. Stocks on the MOVE-Mondelez, IDEX, Merchants Bancorp

Reuters
·
Jul 29

Moleculin Biotech Files Registration Statement for Public Offering; Shares Fall

MT Newswires Live
·
Jul 29

Moleculin Biotech Reports Positive Preliminary Unblinded Efficacy Results in Miracle Trial for Relapsed, Refractory AML

Reuters
·
Jul 06

Analysts Are Bullish on Top Healthcare Stocks: ADC Therapeutics (ADCT), Moleculin Biotech (MBRX)

TIPRANKS
·
Jul 02

Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR) and Moleculin Biotech (MBRX)

TIPRANKS
·
Jul 01

Moleculin Biotech Reports Promising Annamycin AML Trial Data

TIPRANKS
·
Jun 30

Moleculin Says Interim Phase 2/3 Miracle Trial Shows Annamycin Boosts Complete Remission in Relapsed/refractory AML

Reuters
·
Jun 30

Moleculin Reports Positive Phase 2/3 Miracle Interim Results, with Annamycin Complete Remission Rates 3-fold Greater than Control

THOMSON REUTERS
·
Jun 30

Moleculin market research shows oncologists likely to prescribe Annamycin in relapsed/refractory AML

Reuters
·
Jun 05

Moleculin enrolls 45th patient in Phase 2B/3 MIRACLE trial of Annamycin combo for relapsed AML

Reuters
·
Jun 04

Moleculin says pooled ASCO data show no detectable cardiotoxicity with Annamycin at high cumulative exposure

Reuters
·
May 29

Moleculin Biotech Releases Updated Investor Information Presentation

TIPRANKS
·
May 26

Moleculin says ASCO accepts pooled cardiac safety analysis for Annamycin poster

Reuters
·
May 22

Moleculin Biotech Q1 EPS $(3.54) Misses $(1.57) Estimate

Benzinga Earnings
·
May 15

Moleculin Biotech Q1 net loss widens as R&D costs rise

Reuters
·
May 15

Moleculin Biotech Q1 EPS USD -3.54

THOMSON REUTERS
·
May 15

Moleculin reports 40% blinded remission rate in pivotal MIRACLE AML trial

Reuters
·
May 15

Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal Miracle Trial

THOMSON REUTERS
·
May 15

Moleculin Biotech Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 15